Prognostic value of morphology and hormone receptor status in breast cancer -: a population-based study

被引：34

作者：

Allemani, C

Sant, M

Berrino, F

Aareleid, T

Chaplain, G

Coebergh, JW

Colonna, M

Contiero, P

Danzon, A

Federico, M

Gafà, L

Grosclaude, P

Hédelin, G

Macè-Lesech, J

Garcia, CM

Paci, E

Raverdy, N

Tretarre, B

Williams, EMI

机构：

[1] Ist Nazl Studio & Cura Tumori, Epidemiol Unit, I-20133 Milan, Italy

[2] Inst Clin & Expt Med, Dept Epidemiol & Biostat, EE-11619 Tallinn, Estonia

[3] N Estonian Reg Hosp Fdn Canc Ctr, Estonian Canc Registry, EE-11619 Tallinn, Estonia

[4] Fac Med, Ctr Univ Epidemiol Populat, Cote dOr Breast & Gynaecol Canc Registry, F-21000 Dijon, France

[5] Eindhoven Canc Registry, Comprehens Canc Ctr S, NL-5600 EA Eindhoven, Netherlands

[6] Isere Canc Registry, F-38240 Meylan, France

[7] Ist Nazl Studio & Cura Tumori, Lombardy Canc Registry, I-20133 Milan, Italy

[8] CHU Besancon, Doubs Canc Registry, F-25030 Besancon, France

[9] Policlin, Modena Canc Registry, I-41100 Modena, Italy

[10] Ragusa Canc Registry, I-97100 Ragusa, Italy

[11] Tam Canc Registry Rech Epidemiol & Prevent, F-81001 Albi, France

[12] Fac Med Strasbourg, Bas Rhin Canc Registry, Lab Epidemiol & Sante Publ, F-67085 Strasbourg, France

[13] Ctr Francois Baclesse, Calvados Canc Registry, F-14021 Caen, France

[14] Escuela Andaluza SAlud Publ, Granada Canc Registry, E-18080 Granada, Spain

[15] Ao Careggi CSPO, UO Epidemiol Clin & Descritt, Tuscany Canc Registry, I-50135 Florence, Italy

[16] CHR Nord, Assoc Rech Epidemiol Picardie, Somme Canc Registry, F-80054 Amiens 1, France

[17] Herault Canc Registry, F-34298 Montpellier 5, France

[18] Univ Liverpool, Mersey Canc Registry, Liverpool L69 3GB, Merseyside, England

来源：

BRITISH JOURNAL OF CANCER | 2004年 / 91卷 / 07期

关键词：

breast cancer; population-based studies; relative survival; predictive factors; relative excess risk of death;

D O I：

10.1038/sj.bjc.6602153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We analysed the 5-year relative survival among 4473 breast cancer cases diagnosed in 1990-1992 from cancer registries in Estonia, France, Italy, Spain, the Netherlands and the UK. Among eight categories based on ICD-O codes (infiltrating ductal carcinoma, lobular plus mixed carcinoma, comedocarcinoma, 'special types', medullary carcinoma, not otherwise specified (NOS) carcinoma, other carcinoma and cancer without microscopic confirmation), the 5-year relative survival ranged from 66% (95% CI 61-71) for NOS carcinoma to 95% (95% CI 90-100) for special types (tubular, apocrine, cribriform, papillary, mucinous and signet ring cell); 27% (95% CI 18-36) for cases without microscopic confirmation. Differences in 5-year relative survival by tumor morphology and hormone receptor status were modelled using a multiple regression approach based on generalised linear models. Morphology and hormone receptor status were confirmed as significant survival predictors in this population-based study, even after adjusting for age and stage at diagnosis.

引用

页码：1263 / 1268

页数：6

共 50 条

[21] Estrogen Receptor Status in Relation to Risk of Contralateral Breast Cancer-A Population-Based Cohort Study
Sandberg, Maria E. C.
Hall, Per
Hartman, Mikael
Johansson, Anna L. V.
Eloranta, Sandra
Ploner, Alexander
Czene, Kamila
PLOS ONE, 2012, 7 (10):
[22] Which women with breast cancer do, and do not, undergo receptor status testing? A population-based study
Cancela, Marianna de Camargo
Comber, Harry
Sharp, Linda
CANCER EPIDEMIOLOGY, 2015, 39 (05) : 778 - 782
[23] Prognostic factors for survival in metastatic breast cancer by hormone receptor status
A. B. G. Kwast
A. C. Voogd
M. B. E. Menke-Pluijmers
S. C. Linn
G. S. Sonke
L. A. Kiemeney
S. Siesling
Breast Cancer Research and Treatment, 2014, 145 : 503 - 511
[24] Prognostic factors for survival in metastatic breast cancer by hormone receptor status
Kwast, A. B. G.
Voogd, A. C.
Menke-Pluijmers, M. B. E.
Linn, S. C.
Sonke, G. S.
Kiemeney, L. A.
Siesling, S.
BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (02) : 503 - 511
[25] Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study
O. Abdel-Rahman
Clinical and Translational Oncology, 2020, 22 : 1645 - 1650
[26] Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study
Abdel-Rahman, O.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (09): : 1645 - 1650
[27] Population-based hormone receptor-specific incidence trends of breast cancer in Germany
Rusner, Carsten
Bandemer-Greulich, Ulrike
Engel, Jutta
Stegmaier, Christa
Zawinell, Anette
Holleczek, Bernd
Katalinic, Alexander
Kuss, Oliver
Schmidt-Pokrzywniak, Andrea
Schubert-Fritschle, Gabriele
Tillack, Anett
Stang, Andreas
MATURITAS, 2012, 73 (02) : 152 - 157
[28] Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study
de Wild, Sabine R.
Koppert, Linetta B.
de Munck, Linda
Peeters, Marie-Jeanne T. F. D. Vrancken
Siesling, Sabine
Smidt, Marjolein L.
Simons, Janine M.
BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (02) : 277 - 288
[29] Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study
Sabine R. de Wild
Linetta B. Koppert
Linda de Munck
Marie-Jeanne T. F. D. Vrancken Peeters
Sabine Siesling
Marjolein L. Smidt
Janine M. Simons
Breast Cancer Research and Treatment, 2024, 204 : 277 - 288
[30] Population-based study of hormone receptor status comparing Oncotype DX with standard immunohistochemistry
Baehner, F. L.
Maddala, T.
Alexander, C.
Gown, A. M.
Goldstein, L. C.
Achacoso, N. S.
Shak, S.
Quesenberry, C. P.
Habel, L. A.
BREAST CANCER RESEARCH, 2009, 11 : S11 - S11

← 1 2 3 4 5 →